Avalo Therapeutics: Contrarian 'Buy' Ahead Of Abdakibart's Phase 3Seeking Alpha · 3 hr ago
This Avalo Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For FridayBenzinga · 1 day ago
Avalo Therapeutics (NASDAQ:AVTX) Hits New 52-Week Low – Time to Sell?Defense World · Oct 16, 2026
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Sep 29, 2026
Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 CongressGlobeNewsWire · Sep 23, 2026
Christopher Ryan Sullivan Sells 12,394 Shares of Avalo Therapeutics (NASDAQ:AVTX) StockDefense World · Sep 20, 2026Avalo Therapeutics, Inc. is a precision medicine company in the clinical development phase, dedicated to identifying, advancing, and marketing specialized treatments for patients experiencing critical unmet medical needs across the fields of immunology, immuno-oncology, and rare genetic disorders. Among its key pipeline assets is AVTX-002, a fully human monoclonal antibody designed to inhibit LIGHT. This drug is currently undergoing Phase II clinical trials for non-eosinophilic asthma and inflammatory bowel diseases, specifically moderate to severe Crohn's disease and ulcerative colitis.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.58 | -$0.83 | Miss |
| May 13, 2026 | -$1.00 | -$0.98 | Beat |
| Mar 23, 2026 | -$1.54 | -$0.74 | Beat |
| Nov 6, 2025 | -$1.67 | -$2.19 | Miss |
| Aug 7, 2025 | -$1.43 | -$1.92 | Miss |
| May 12, 2025 | -$1.07 | -$1.25 | Miss |